In a single-arm, nonrandomized phase II trial (HER2-based strategy in stomach cancer (HERBIS)–1) performed in Japan [6], trastuzumab in combination with S-1 plus cisplatin yielded a confirmed ORR of 68%, with a median OS and a median PFS of 16.0 and 7.8 months, respectively, in HER2-positive AGC patients with measurable lesions, with these results being similar to those of the ToGA trial [2]. This evidence concerns the gene ERBB2 and gastric cancer.